Argus raised the firm’s price target on Regeneron to $1,060 from $920 and keeps a Buy rating on the shares. The company stands to benefit from positive developments over the next 12 months, including potential FDA and European Commission approvals of linvoseltamab as a treatment for relapsed/refractory multiple myeloma and for odronextamab for patients with relapsed/refractory follicular lymphoma and patients with relapsed/refractory diffuse large B-cell lymphoma, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron exec LaRosa sells 1,000 common shares
- Regeneron Announces Investor Conference Presentations
- Regeneron Pharmaceuticals Is Worried About This – Should You Be Worried Too?
- Regeneron price target raised to $1,135 from $1,045 at Truist
- Regeneron price target raised to $1,082 from $1,055 at BMO Capital